nach oben

Erschienen in:

13.09.2020 | Review Article

The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas

verfasst von: Juan Carlos Prieto Prieto, Juan Antonio Vallejo Casas, Eleftheria Hatzimichael, Andreas Fotopoulos, Dimitrios-Nikiforos Kiortsis, Chrissa Sioka

Erschienen in: Annals of Nuclear Medicine | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Lymphomas are the most common hematological malignancies and are further distinguished in Hodgkin lymphoma (HL) and non-Hodgkin (NHL). For staging purposes and for assessing response to treatment, the Lugano classification is currently used, both for HL and NHL patients, whereas for the assessment of prognosis, several prognostic systems exist, such as the international prognostic index (IPI) and revised-IPI for diffuse large B cell lymphomas, follicular lymphoma IPI (FLIPI)-1 and 2 for follicular lymphomas, and the international prognostic score for advanced HL. The aim of this systematic review was to determine the significance of the metabolic FDG PET/CT parameters, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), in monitoring therapeutic interventions and prognostic outcome of patients with HL and NHL. We performed a systematic search on the literature and selection of articles concerning treatment evaluation, response and survival in association with MTV and TLG in patients with lymphomas. Our review documented that in most studies, baseline MTV and TLG were predictive of treatment response, progression-free survival (PFS) and overall survival (OS) for both HL and NHL patients. There were conflicting results for the value of interim determination of MTV and TLG. Our conclusion was that combination of baseline MTV and TLG parameters with prognostic scoring systems, such as IPI, or FLIPI-1 and -2, will add additional predictive power for response and prognosis in lymphoma patients.

Nur mit Berechtigung zugänglich

Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet. 2017;390(10091):298–310.PubMed

Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.PubMedPubMedCentral

Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep. 1977;61(6):1023–7.PubMed

Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkin's lymphomas. Semin Oncol. 1990;17(1):43–50.PubMed

Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373–80.PubMed

Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350(18):1828–37.PubMed

Relander T, Johnson NA, Farinha P, et al. Prognostic factors in follicular lymphoma. J Clin Oncol. 2010;28(17):2902–13.PubMed

Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.PubMed

Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–622.PubMed

10.

Bachy E, Maurer MJ, Habermann TM, et al. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018;132(1):49–58.PubMedPubMedCentral

11.

Adams HJA, Kwee TC. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma. Semin Oncol. 2017;44(6):404–19.PubMed

12.

Sioka C, Assimakopoulos A, Fotopoulos A. The diagnostic role of (18)F fluorodeoxyglucose positron emission tomography in patients with fever of unknown origin. Eur J Clin Invest. 2015;45(6):601–8.PubMed

13.

Katsanos AH, Alexiou GA, Fotopoulos AD, Jabbour P, Kyritsis AP, Sioka C. Performance of 18F-FDG, 11C-methionine, and 18F-FET PET for Glioma grading: a meta-analysis. Clin Nucl Med. 2019;44(11):864–9.PubMed

14.

Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers (Basel). 2014;6(4):1821–89.

15.

Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2012;29(14):1844–54.

16.

Sioka C. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr. 2013;172(6):733–8.PubMed

17.

Kim HJ, Lee R, Choi H, et al. Application of quantitative indexes of FDG PET to treatment response evaluation in indolent lymphoma. Nucl Med Mol Imaging. 2018;52(5):342–9.PubMedPubMedCentral

18.

Ilyas H, Mikhaeel NG, Dunn JT, et al. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(7):1142–54.PubMedPubMedCentral

19.

Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget. 2017;8(59):99587–600.PubMedPubMedCentral

20.

Zhou M, Chen Y, Huang H, Zhou X, Liu J, Huang G. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget. 2016;7(50):83544–53.PubMedPubMedCentral

21.

Camacho MR, Etchebehere E, Tardelli N, et al. Validation of a multifocal segmentation method for measuring metabolic tumor volume in Hodgkin lymphoma. J Nucl Med Technol. 2020;48(1):30–5.PubMed

22.

Xie M, Zhai W, Cheng S, Zhang H, Xie Y, He W. Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma. Hematology. 2016;21(9):99–105.PubMed

23.

Islam P, Goldstein J, Flowers CR. PET-derived tumor metrics predict DLBCL response and progression-free survival. Leuk Lymphoma. 2019;60(8):1965–71.PubMedPubMedCentral

24.

Xie M, Wu K, Liu Y, Jiang Q, Xie Y. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants. Med Oncol. 2015;32(1):446.PubMed

25.

Garcia Vicente AM, Bellon Guardia M, Soriano Castrejon A, et al. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences. Rev Esp Med Nucl Imagen Mol. 2012;31(1):22–7.PubMed

26.

Kwon SH, Kang DR, Kim J, et al. Prognostic value of negative interim 2-[(1)(8)F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma. Clin Radiol. 2016;71(3):280–6.PubMed

27.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.PubMed

28.

Guo B, Tan X, Ke Q, Cen H. Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis. PLoS ONE. 2019;14(1):e0210224.PubMedPubMedCentral

29.

Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018;131(1):84–94.PubMedPubMedCentral

30.

Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. Am J Nucl Med Mol Imaging. 2013;3(3):272–81.PubMedPubMedCentral

31.

Song MK, Yang DH, Lee GW, et al. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. Leuk Res. 2016;42:1–6.PubMed

32.

Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–19.PubMedPubMedCentral

33.

Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119(6):1195–202.PubMed

34.

Kim J, Hong J, Kim SG, et al. Prognostic value of metabolic tumor volume estimated by (18) F-FDG positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma of stage II or III disease. Nucl Med Mol Imaging. 2014;48(3):187–95.PubMedPubMedCentral

35.

Parvez A, Tau N, Hussey D, Maganti M, Metser U. (18)F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival. Ann Nucl Med. 2018;32(6):410–6.PubMed

36.

Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91(5):697–703.PubMed

37.

Ding CY, Guo Z, Sun J, Yang WP, Li TR. Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma. Zhonghua Zhong Liu Za Zhi. 2018;40(7):528–33.PubMed

38.

Adams HJ, de Klerk JM, Fijnheer R, et al. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma. Eur J Haematol. 2015;94(6):532–9.PubMed

39.

Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur J Haematol. 2014;92(5):382–9.PubMed

40.

Park YS, Lee SM, Park JS, Bae SK, Shim HK, Lee WS. Evaluating the predictive ability of initial staging F-18 FDG PET/CT for the prognosis of non-Hodgkin Malignant lymphoma patients who underwent stem cell transplantation. Nucl Med Mol Imaging. 2018;52(3):216–23.PubMed

41.

Wu X, Pertovaara H, Korkola P, et al. Early interim PET/CT predicts post-treatment response in diffuse large B-cell lymphoma. Acta Oncol. 2014;53(8):1093–9.PubMed

42.

Yang DH, Ahn JS, Byun BH, et al. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013;92(4):471–9.PubMed

43.

Zhang YY, Chen WY, Cui YP, et al. Value of (18)F-FDG PET/CT scan quantization parameters for prognostic evaluation of patients with diffuse large B-cells lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;26(5):1342–2249.PubMed

44.

Park S, Moon SH, Park LC, et al. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. Am J Hematol. 2012;87(9):937–40.PubMed

45.

Onate-Ocana LF, Cortes V, Castillo-Llanos R, et al. Metabolic tumor volume changes assessed by interval (18)fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma. Oncol Lett. 2018;16(2):1411–8.PubMedPubMedCentral

46.

Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016;280(1):220–9.PubMedPubMedCentral

47.

Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34(30):3618–26.PubMed

48.

Zhou Y, Zhao Z, Li J, et al. Prognostic values of baseline, interim and end-of therapy (18)F-FDG PET/CT in patients with follicular lymphoma. Cancer Manag Res. 2019;11:6871–85.PubMedPubMedCentral

49.

Annunziata S, Cuccaro A, Tisi MC, Hohaus S, Rufini V. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2018;32(5):372–7.PubMed

50.

Tatsumi M, Isohashi K, Matsunaga K, et al. Volumetric and texture analysis on FDG PET in evaluating and predicting treatment response and recurrence after chemotherapy in follicular lymphoma. Int J Clin Oncol. 2019;24(10):1292–300.PubMed

51.

Adams HJA, Nievelstein RAJ, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95(1):11–8.PubMed

52.

Jung SH, Ahn JS, Kim YK, et al. Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer. 2015;15:198.PubMedPubMedCentral

53.

Song MK, Chung JS, Yhim HY, et al. Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma. Oncotarget. 2017;8(45):79337–46.PubMedPubMedCentral

54.

Wang H, Shen G, Jiang C, Li L, Cui F, Tian R. Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: a meta-analysis. PLoS ONE. 2018;13(3):e0194435.PubMedPubMedCentral

55.

Pinnix CC, Ng AK, Dabaja BS, et al. Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. Blood Adv. 2018;2(11):1334–433.PubMedPubMedCentral

56.

Ceriani L, Martelli M, Conconi A, et al. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. Br J Haematol. 2017;178(4):588–91.PubMed

57.

Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950–6.PubMed

58.

Albano D, Bosio G, Bianchetti N, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. Ann Nucl Med. 2019;33(7):449–58.PubMed

59.

Albano D, Bosio G, Camoni L, et al. Prognostic role of baseline (18) F-FDG PET/CT parameters in MALT lymphoma. Hematol Oncol. 2019;37(1):39–46.PubMed

60.

Albano D, Bosio G, Pagani C, et al. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging. 2019;46(1):87–96.PubMed

61.

Albano D, Re A, Tucci A, Giubbini R, Bertagna F. Prognostic role of DeltaMTV and DeltaTLG in Burkitt lymphoma. Ann Nucl Med. 2019;33(4):280–7.PubMed

62.

Watanabe S, Manabe O, Hirata K, et al. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD). BMC Cancer. 2016;16:635.PubMedPubMedCentral

63.

Okuyucu K, Ozaydin S, Alagoz E, et al. Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphoma. Radiol Oncol. 2016;50(4):360–9.PubMedPubMedCentral

64.

Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis. Am J Otolaryngol. 2018;39(1):1–5.PubMed

65.

Wu LL, Liang JH, Wang L, Xu W, Ding CY. Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma. Zhonghua Zhong Liu Za Zhi. 2019;41(11):831–6.PubMed

66.

Alagoz E, Okuyucu K, Ince S, et al. Uptake patterns of untreated primary gastrointestinal extranodal lymphomas on initial staging (18)F-FDG PET/CT and metabolic tumor parameters. Mol Imaging Radionucl Ther. 2017;26(3):83–92.PubMedPubMedCentral

67.

Kim CY, Hong CM, Kim DH, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (1)(8)F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40(9):1321–9.PubMed

68.

Castello A, Grizzi F, Qehajaj D, Rahal D, Lutman F, Lopci E. (18)F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leuk Lymphoma. 2019;60(2):367–75.PubMed

69.

Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma. Cancer Sci. 2013;104(12):1656–61.PubMed

70.

Milgrom SA, Dong W, Akhtari M, et al. Chemotherapy response assessment by FDG-PET-CT in early-stage classical Hodgkin lymphoma: moving beyond the five-point Deauville score. Int J Radiat Oncol Biol Phys. 2017;97(2):333–8.PubMed

71.

Moskowitz AJ, Schoder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130(20):2196–203.PubMedPubMedCentral

72.

Prochazka V, Gawande RS, Cayci Z, et al. Positron emission tomography-based assessment of metabolic tumor volume predicts survival after autologous hematopoietic cell transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2018;24(1):64–70.PubMed

73.

Mettler J, Muller H, Voltin CA, et al. Metabolic tumour volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med. 2018;2:207–11.

Titel: The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas
verfasst von: Juan Carlos Prieto Prieto
Juan Antonio Vallejo Casas
Eleftheria Hatzimichael
Andreas Fotopoulos
Dimitrios-Nikiforos Kiortsis
Chrissa Sioka
Publikationsdatum: 13.09.2020
Verlag: Springer Singapore
Erschienen in: Annals of Nuclear Medicine / Ausgabe 10/2020
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-020-01521-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

SPECT-CT visualization and biopsy of sentinel lymph nodes in patients with stage IAB–IIA cervical cancer

Evaluating and comparing the image quality and quantification accuracy of SiPM-PET/CT and PMT-PET/CT

Recent advances in cardiac positron emission tomography for quantitative perfusion analyses and molecular imaging

Role of carbonated water technique to enhance Tc-99m tetrofosmin myocardial perfusion imaging by reducing subdiaphragmatic artefacts

Detection of sub-centimeter lesions using digital TOF-PET/CT system combined with Bayesian penalized likelihood reconstruction algorithm

Sentinel lymph node biopsy in muscle-invasive bladder cancer: single-center experience